Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ION904 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| ION904 | EXPERIMENTAL | Up to 4 monthly doses of ION904 will be administered by subcutaneous (SC) injection. |
| Placebo | PLACEBO_COMPARATOR | Up to 4 monthly doses of placebo will be administered by SC injection. |
| Name | Type | Description |
|---|---|---|
| ION904 | DRUG | ION904 will be administered by SC injection. |
| Placebo | DRUG | Placebo will be administered by SC injection. |
General Inclusion Criteria: 1. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), she uses a highly effective contraceptive method. Aged 18 - 75 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent...
ION904 is an investigational small molecule being developed by Ionis Pharmaceuticals for the treatment of hypertension. It has been studied in healthy volunteers and in participants with uncontrolled hypertension. The drug is administered via subcutaneous injection on a monthly basis.
ION904 is developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the safety, tolerability, and efficacy of this investigational drug.
ION904 has completed Phase 1 and Phase 2 clinical trials. The Phase 1 study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The Phase 2 study evaluated safety, tolerability, and efficacy in participants with uncontrolled hypertension. The drug is not FDA approved and remains investigational.
ION904 has been studied in two completed clinical trials. NCT04731623 was a Phase 1 study in healthy volunteers in Canada. NCT05314439 was a Phase 2 study in participants with uncontrolled hypertension in the United States. Both trials were randomized, double-blind, and placebo-controlled.
ION904 is administered via subcutaneous injection. In the Phase 2 clinical trial, the drug was given on a monthly basis to participants with uncontrolled hypertension. The Phase 1 study in healthy volunteers also evaluated subcutaneous administration of the drug.